-
-
NCT00210925
-
Primary Citation
-
Data Specification Not Available
Trial Information
Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous SystemEnrollment371% Female26.9%% White84.9%
Product ClassAnticonvulsantsSponsor Protocol NumberCAPSS-278Data PartnerJohnson & JohnsonCondition StudiedAlcoholismMean/Median Age (Years)47.3
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0980 : Can Quantum Machine Learning Accurately Predict the Therapeutic Outcomes of Drugs Based on Clinical Data?
- 2024-0332 : Prediction of Likely Responders to Topiramate to further personalized treatment for Alcohole Use Disorder
- 2020-4276 : Psychiatric Symptoms as Adverse Events of Topiramate Therapy: Systematic Review and Meta-Analysis